Ananda Developments Plc - iCAN Israel-Cannabis Ltd Update
(“Ananda” or the “Company”)
iCAN Israel-Cannabis Ltd Update
The directors of (NEX: ANA), are pleased to provide shareholders with the following update on Ananda’s investee company, iCAN (“iCAN”). Ananda owns of Convertible Loan Notes in iCAN, converting at a 20% discount to a valuation of .
iCAN Israel Cannabis has raised a further from a group of based investors through the issue of convertible loan notes. The convertible loan notes are convertible at a price equal to a price per share based on a valuation of .
The full announcement can be found at:https://www.prnewswire.com/news-releases/ican-secures-financing-through-a-convertible-loan-of-cad-4-million-us3-million-300822764.html?tc=eml_cleartime
, Chief Executive Officer of Ananda, said: “We congratulate Saul and his team on this financing at a significant premium to Ananda’s entry valuation. It is a testament to Saul’s vision and leadership in the cannabis eco system that he is able to attract this capital and continue to be the pre-eminent voice in the global cannabis landscape.”
The directors of the Company accept responsibility for the contents of this announcement.
--ENDS—
Ananda Developments PLC +44 (0)739 269 6517
(Chief Executive Officer)
Jeremy Sturgess-Smith (Investor Relations)
Peterhouse Capital Limited +44 (0)20 7469 0930
Corporate Advisory
and
Corporate Broking
and Duncan Vasey
About
Ananda Developments invests in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the , as well as other countries around the world, changing their laws to allow for products containing constituents of Medical Cannabis to be developed, approved and sold.
A copy of the Company’s Admission Document is available at and at .www.anandadevelopments.comwww.nexexchange.com
Ananda’s investment strategy is to invest in companies, projects or products that are either progressing medical or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE